Inovio Pharmaceuticals, Inc. (INO) Income Statement Analysis

See more : Planet Communications Asia Public Company Limited (PLANET.BK) Income Statement Analysis – Financial Results

Complete financial analysis of Inovio Pharmaceuticals, Inc. (INO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inovio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Otsuka Corporation (OSUKF) Income Statement Analysis – Financial Results
Brunel International N.V. (BRNL.AS) Income Statement Analysis – Financial Results
CAFFYNS PLC 7% CUM 1ST PRF #1 (78GL.L) Income Statement Analysis – Financial Results
China Display Optoelectronics Technology Holdings Limited (0334.HK) Income Statement Analysis – Financial Results
CRRC Corporation Limited (601766.SS) Income Statement Analysis – Financial Results

Inovio Pharmaceuticals, Inc. (INO)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.inovio.com

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999
Revenue	832.01K	10.26M	1.77M	7.41M	4.11M	30.48M	42.22M	35.37M	40.57M	10.46M	13.47M	4.12M	9.80M	6.14M	9.12M	2.10M	4.81M	3.47M	5.47M	1.17M	80.53K	189.52K	4.45M	5.08M	8.30M
Cost of Revenue	3.50M	5.50M	4.73M	94.25M	88.02M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	225.00K	206.25K	0.00	0.00	0.00	1.93M	1.46M	1.20M
Gross Profit	-2.67M	4.77M	-2.96M	-86.83M	-83.91M	30.48M	42.22M	35.37M	40.57M	10.46M	13.47M	4.12M	9.80M	6.14M	9.12M	2.10M	4.81M	3.24M	5.26M	1.17M	80.53K	189.52K	2.53M	3.62M	7.10M
Gross Profit Ratio	-321.09%	46.44%	-166.56%	-1,171.66%	-2,040.54%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	93.51%	96.23%	100.00%	100.00%	100.00%	56.77%	71.29%	85.54%
Research & Development	86.68M	187.65M	249.24M	94.25M	88.02M	95.26M	98.57M	88.71M	57.79M	34.10M	21.37M	17.98M	20.03M	13.26M	9.41M	5.75M	9.63M	8.51M	11.45M	6.55M	2.15M	2.47M	459.71K	6.98M	8.10M
General & Administrative	47.58M	90.19M	53.75M	37.25M	27.20M	29.32M	28.29M	23.89M	18.06M	15.86M	13.64M	10.78M	11.99M	12.11M	13.67M	10.01M	11.08M	8.08M	5.98M	6.13M	4.57M	3.66M	0.00	5.61M	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	47.58M	90.19M	53.75M	37.25M	27.20M	29.32M	28.29M	23.89M	18.06M	15.86M	13.64M	10.78M	11.99M	12.11M	13.67M	10.01M	11.08M	8.08M	5.98M	6.13M	4.57M	3.66M	6.62M	5.61M	5.50M
Other Expenses	-1.70M	-3.86M	343.37K	3.42M	496.20K	360.80K	806.82K	127.55K	177.56K	348.14K	-45.63M	1.98M	0.00	0.00	9.28M	4,672.53B	7,547.58B	225.00K	206.25K	5.60M	2.07M	2.28M	0.00	566.36K	400.00K
Operating Expenses	132.56M	277.84M	302.99M	131.49M	115.22M	124.57M	126.86M	112.60M	75.86M	49.95M	35.01M	28.76M	32.02M	25.36M	23.08M	15.76M	20.71M	16.81M	17.64M	12.68M	6.71M	6.12M	7.08M	13.15M	14.00M
Cost & Expenses	144.77M	277.84M	302.99M	131.49M	115.22M	124.57M	126.86M	112.60M	75.86M	49.95M	35.01M	28.76M	32.02M	25.36M	23.08M	15.76M	20.71M	16.81M	17.64M	12.68M	6.71M	6.12M	9.01M	14.61M	15.20M
Interest Income	8.13M	4.78M	3.36M	3.31M	2.61M	2.26M	1.61M	1.40M	305.07K	0.00	132.21K	166.11K	0.00	0.00	0.00	0.00	1.27M	867.07K	207.68K	247.56K	65.50K	32.32K	443.63K	556.19K	556.19K
Interest Expense	1.22M	1.25M	1.94M	8.70M	7.95M	346.09K	4.56M	139.25K	0.00	0.00	88.17M	0.00	34.29K	0.00	10.50M	0.00	0.00	0.00	3.33M	0.00	20.48K	5.45K	-20.38K	24.34K	24.34K
Depreciation & Amortization	3.50M	5.50M	4.73M	4.63M	5.52M	5.00M	3.47M	3.09M	1.92M	1.57M	2.10M	1.99M	2.01M	2.11M	1.68M	993.03K	954.64K	911.64K	799.32K	573.04K	584.41K	619.34K	0.00	566.36K	400.00K
EBITDA	-130.39M	-270.90M	-296.56M	-149.56M	-107.34M	-89.80M	-84.74M	-74.15M	-33.37M	-37.93M	-19.45M	-22.65M	-21.64M	-17.11M	-13.96M	-11.97M	-10.19M	-12.43M	-11.38M	-10.94M	-6.05M	-5.28M	-5.58M	-8.37M	-8.97M
EBITDA Ratio	-15,671.81%	-2,616.89%	-16,528.13%	-1,027.76%	-2,567.66%	-293.47%	-196.54%	-212.84%	-85.14%	-366.03%	179.60%	-626.01%	-301.08%	-318.79%	-120.85%	-606.13%	-382.00%	-358.53%	-147.17%	-937.17%	-7,511.39%	-2,787.69%	-125.22%	-164.87%	-81.93%
Operating Income	-135.23M	-267.57M	-301.22M	-124.08M	-111.11M	-94.09M	-83.64M	-76.24M	-34.28M	-39.50M	-19.54M	-23.49M	-21.64M	-19.22M	-13.96M	-13.66M	-15.90M	-13.35M	-15.51M	-11.51M	-6.63M	-5.93M	-5.58M	-9.53M	-6.90M
Operating Income Ratio	-16,253.01%	-2,607.35%	-16,972.34%	-1,674.25%	-2,702.10%	-308.68%	-198.11%	-215.55%	-84.50%	-377.71%	-145.12%	-570.42%	-220.91%	-312.79%	-153.04%	-651.14%	-330.68%	-384.82%	-283.63%	-986.27%	-8,237.11%	-3,131.53%	-125.22%	-187.79%	-83.13%
Total Other Income/Expenses	109.31K	-10.08M	-2.01M	-38.81M	-9.70M	-706.88K	-4.56M	2.50M	3.08M	3.36M	-46.54M	3.78M	6.33M	1.51M	-10.50M	692.84K	3.42M	867.07K	2.44K	247.56K	6.63M	26.87K	-3.29M	-597.18K	2.93M
Income Before Tax	-135.12M	-277.65M	-303.22M	-162.89M	-120.81M	-94.80M	-88.21M	-73.74M	-31.20M	-36.14M	-66.08M	-19.71M	-12.95M	-17.71M	-24.46M	-13.61M	-12.48M	-14.48M	-15.50M	-0.66	-0.43	-5.91M	-8.87M	-10.13M	-6.60M
Income Before Tax Ratio	-16,239.87%	-2,705.57%	-17,085.39%	-2,197.89%	-2,938.01%	-311.00%	-208.92%	-208.49%	-76.90%	-345.61%	-490.69%	-478.63%	-132.19%	-288.27%	-268.21%	-648.80%	-259.52%	-417.65%	-283.59%	0.00%	0.00%	-3,117.36%	-199.11%	-199.55%	-79.52%
Income Tax Expense	0.00	10.01M	2.16M	52.20M	-257.34K	2.17M	1.76M	-4.62M	-2.10M	-3.72M	88.12M	-8.11M	-16.28M	-4.08M	11.71M	-741.85K	-8.12M	-867.07K	6.45M	-537.76K	-1.99M	56.78K	0.00	638.17K	-600.00K
Net Income	-135.12M	-287.66M	-305.38M	-215.09M	-120.55M	-96.97M	-88.21M	-73.74M	-29.19M	-36.12M	-66.03M	-19.67M	-15.25M	-17.61M	-24.41M	-12.97M	-11.20M	-12.48M	-15.30M	-10.97M	-4.66M	-5.96M	-8.87M	-9.60M	-6.60M
Net Income Ratio	-16,239.87%	-2,803.13%	-17,207.13%	-2,902.17%	-2,931.76%	-318.12%	-208.92%	-208.49%	-71.94%	-345.44%	-490.29%	-477.56%	-155.72%	-286.65%	-267.67%	-618.11%	-233.05%	-359.82%	-279.79%	-940.19%	-5,792.83%	-3,147.32%	-199.11%	-189.07%	-79.52%
EPS	-6.09	-14.47	-17.55	-16.64	-14.65	-1.05	-1.08	-1.01	-0.43	-0.61	-1.43	-0.58	-0.48	-0.68	-1.31	-1.18	-1.08	-1.58	-3.22	-2.49	-1.40	-2.35	-5.13	-6.80	-5.21
EPS Diluted	-6.09	-14.47	-17.55	-16.64	-14.65	-1.05	-1.08	-1.01	-0.43	-0.61	-1.43	-0.58	-0.48	-0.68	-1.31	-1.18	-1.08	-1.58	-3.22	-2.49	-1.40	-2.35	-5.13	-6.80	-5.21
Weighted Avg Shares Out	22.17M	19.89M	17.40M	12.93M	8.23M	92.35M	81.78M	73.01M	68.20M	59.13M	46.09M	33.91M	31.56M	25.80M	18.68M	10.98M	10.37M	7.88M	4.75M	4.41M	3.33M	2.54M	1.73M	1.41M	1.27M
Weighted Avg Shares Out (Dil)	22.17M	19.89M	17.40M	12.93M	8.23M	92.54M	81.92M	73.21M	68.37M	59.41M	46.09M	34.13M	31.56M	25.80M	18.68M	10.98M	10.37M	7.88M	4.75M	4.41M	3.33M	2.54M	1.73M	1.41M	1.27M

Why Shares of Inovio Pharmaceuticals Were Down Tuesday

April 4, 2023fool.com

Inovio said it has enough cash to fund operations into the first quarter of 2025. The company focuses on DNA medicines to treat HPV diseases, cancer, and infectious diseases.

INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 3, 2023prnewswire.com

PLYMOUTH MEETING, Pa. , March 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D.

Inovio Pharmaceuticals, Inc. (INO) Q4 2022 Earnings Call Transcript

March 1, 2023seekingalpha.com

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Thomas Hong - Manager-Investor Communications Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Peter Kies -...